In contrast, increased BTG2 and LAMP3 expression are accompanied by increased sensitivity of tumor cells to chemotherapeutic agents, such as axitinib, oxaliplatin, and fluorouracil (Figures 9F,G). This evidence concerns the gene BTG2 and neoplasm.